An observational study in Sepsis, Immunologic Paralysis and Immunologic Suppression, sponsored by Charles University, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Charles University, Czech Republic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Shock, Septic with a site in Czechia — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Czechia.
Among the 19 studies in Shock, Septic with a site in Czechia, this one is one of 2 that started in 2020, is one of 8 observational ones, and was the 15th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →2 of the 19 studies in Shock, Septic with a site in Czechia are open now. Recruiting first, the newest first:
University Hospital Pilsen · Sites in Czechia
Ages 18–90
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 108 across 408 observational studies indexed under Shock, Septic.
Median enrollment 277 across the 11 interventional studies, 95 across the 8 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Charles University, Czech Republic has 4 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
1 of the studies in Shock, Septic with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06634069University Hospital PilsenStudy SOLACE SEPSIS | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Shock, Septic with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 200 is above the median of 108 across 408 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
sepsis/septic shock according SEPSIS-3 definition
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
target population
Other: transcriptomics · Other: flow-cytometry · Other: cytokines
demographically-matched control group
Other: transcriptomics · Other: flow-cytometry · Other: cytokines
control group
Other: transcriptomics · Other: flow-cytometry · Other: cytokines
transcriptomics
peripheral blood myeloid cells and lymphocytes flow-cytometry
peripheral blood cytokine analysis
Immune response description - flow cytometry
Detailed description of immune response analyzed by mean of flow cytometry
Time frame: 2024 - 2026
Immune response description - transcriptomics
Detailed description of immune response analyzed by mean of transcriptomic analysis
Time frame: 2024 - 2026
Immune response description - ELISA
Detailed description of immune response analyzed by mean of ELISA
Time frame: 2024 - 2026
Diagnostic "immune status" panel
Diagnostic tool for immune status assessment
Time frame: 2026 - 2028
Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.
Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 87 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2025 → Dec 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charles University, Czech Republic →